The 22nd Bio€quity Europe
16-18 May, 2022
Milan, Italy
ENYO Pharma will attend the 22nd Bio€quity Europe, the Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs.
ENYO Pharma’s team will reconnect with investors and partners to accelerate the clinical development of its lead compound Vonafexor focused on kidney and liver diseases.
Jacky Vonderscher will also present “VONAFEXOR, a fibrolytic and anti-inflammatory for the treatment of kidney and liver diseases” in the Hot Topics Track #1 session, 16:30 pm -16:42 pm, May 17
https://conferences.biocentury.com/bioequity-europe
Read next in 'Events'
- The 2024 international workshop on Alport syndrome
- ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
- 6th CKD Summit – Chronic Kidney Disease Drug Development
- ASN Kidney Week
- Alport Connect 2023, the annual Alport syndrome patient and family meeting in US